文献速递糖尿病肥胖与代谢综合征

替尔泊肽对比度拉糖肽或司美格鲁肽对2型糖尿病合并心血管疾病患者主要心血管事件的效果比较

Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations.
PubMed 文献 · Diabetes Care · 2026-01-01

两项目标试验模拟纳入合并ASCVD的T2D成人,比较替尔泊肽与度拉糖肽或司美格鲁肽的心血管结局。替尔泊肽相较度拉糖肽降低改良MACE风险(HR 0.80),主要由全因死亡下降驱动;与司美格鲁肽相比改良MACE风险相似(HR 1.03)。

要点

  • 替尔泊肽较度拉糖肽降低改良MACE风险,HR 0.80(95%CI 0.65-0.99)。
  • 全因死亡下降驱动该差异,替尔泊肽vs度拉糖肽HR 0.60(95%CI 0.43-0.83)。
  • 替尔泊肽与司美格鲁肽的改良MACE风险相似,HR 1.03(95%CI 0.90-1.17)。

核心结论

  • 在常规诊疗的T2D合并ASCVD成人中,替尔泊肽较度拉糖肽与更低的改良MACE风险相关,该关联由全因死亡减少驱动。
  • 替尔泊肽与司美格鲁肽的改良MACE风险似乎相似。

研究设计与样本

  • 第一项比较替尔泊肽与度拉糖肽新使用者,倾向性评分1:1匹配后各9,233对。
  • 第二项比较替尔泊肽与司美格鲁肽新使用者,倾向性评分1:1匹配后各25,266对。
  • 主要结局为改良MACE,即非致死性心肌梗死、非致死性卒中与全因死亡的复合终点。

主要发现

  • 替尔泊肽起始者改良MACE发生率低于度拉糖肽起始者(IR 31.3 vs. 39.4/1000人年;HR 0.80,95%CI 0.65-0.99)。
  • 替尔泊肽较度拉糖肽的全因死亡HR为0.60(95%CI 0.43-0.83)。
  • 事后分析中替尔泊肽较度拉糖肽与更低的肺炎相关住院率相关。
  • 替尔泊肽与司美格鲁肽起始者的改良MACE发生率相似(IR 23.7 vs. 23.2/1000人年;HR 1.03,95%CI 0.90-1.17)。

临床怎么用

  • 在T2D合并ASCVD患者中,选择替尔泊肽而非度拉糖肽可能与更低的改良MACE及全因死亡风险相关。
  • 替尔泊肽与司美格鲁肽在该人群中的改良MACE风险未见明显差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the comparative effectiveness of dulaglutide or semaglutide versus tirzepatide on cardiovascular outcomes in adults with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD). RESEARCH DESIGN AND METHODS: Two target trial emulations included commercially insured adults (June 2022-December 2024) with T2D and ASCVD who initiated subcutaneous tirzepatide, dulaglutide, or semaglutide. The primary outcome was modified major adverse cardiovascular events (MACE), defined as a composite of nonfatal myocardial infarction, nonfatal stroke, and all-cause death. First, new users of tirzepatide and dulaglutide were propensity score (PS) matched one to one. Second, new users of tirzepatide and semaglutide were PS matched one to one. Incidence rates (IRs) per 1,000 person-years and hazard ratios (HRs) were estimated. RESULTS: After PS matching, 9,233 pairs of tirzepatide or dulaglutide initiators and 25,266 pairs of tirzepatide or semaglutide initiators were identified. Tirzepatide initiators experienced a lower rate of modified MACE versus dulaglutide initiators (IR 31.3 vs. 39.4, respectively; HR 0.80 [95% CI 0.65-0.99]), which seemed to be driven by lower all-cause mortality among tirzepatide versus dulaglutide initiators (HR 0.60 [95% CI 0.43-0.83]). In post hoc analyses, tirzepatide was associated with lower rates of pneumonia-related hospitalization when compared with dulaglutide. Rates of modified MACE were similar among tirzepatide and semaglutide initiators (IR 23.7 vs. 23.2, respectively; HR 1.03 [95% CI 0.90-1.17]). CONCLUSIONS: Among adults with T2D and ASCVD in routine care, tirzepatide was associated with a lower risk of modified MACE when compared with dulaglutide, driven by reduction in all-cause mortality. Risks of modified MACE seemed similar with tirzepatide and semaglutide.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Ostrominski JW, Ortega-Montiel J, Wexler DJ, et al. Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations. Diabetes Care. 2026. PMID: 41778928. doi:10.2337/dc25-3063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。